Publications & Presentations Our innovative development programs are backed by sound scientific research. Filter by All Publications Data Presentations Outcomes in Congenital Hyperinsulinism: A Systematic Review Davelyn Hood MD MBA et al. ENDO 2026 06/15/26 Ersodetug (RZ358) in Congenital Hyperinsulinism: Top-Line Results from a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE) Huseyin Demirbilek MD et al. ENDO 2026 06/13/26 A Case Series on the Compassionate Use of Ersodetug, an Insulin Receptor Modulating Antibody, in Patients with Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors Mary Elizabeth Patti MD et al. ENDO 2026 06/13/26 Title: Association of Early-Life Hypoglycemia with Later Neurological Outcomes in Congenital Hyperinsulinism: A US Claims-Based Study Cody Akana et al. ENDO 2026 06/13/26 Top-Line Results From a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE) Diva D. De León-Crutchlow, MD, MSCE Pediatric Endocrine Society (PES) 05/01/26 Preliminary Patient Demographics and Baseline Characteristics From a Phase 3 Study (sunRIZE) of Ersodetug for Hypoglycemia Due to Congenital Hyperinsulinism: Trial in Progress Gopal Saha MBBS et al. ENDO 07/10/25 Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism Huseyin Demirbilek et al. Science Direct 06/13/25 RZ358 (Ersodetug) as a Novel Therapy for Hypoglycemia due to Tumor Hyperinsulinism: Outcomes from an Expanded Access Program for Compassionate Use Jonathan Strosberg MD et al. NANETS 12/05/24 The birth prevalence of congenital hyperinsulinism: a narrative review of the epidemiology of a rare disease David Lapidus et al. S. Karger AG 06/17/24 Topline Results: RZ402-201 Phase 2 Study in Patients with Diabetic Macular Edema (DME) Rezolute Webcast 05/21/24 123
